Dejan Micic to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Dejan Micic has written about Biosimilar Pharmaceuticals.
Connection Strength
1.072
-
Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther. 2017 05; 45(10):1372.
Score: 0.594
-
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis. 2020 Nov; 35(11):2113-2116.
Score: 0.186
-
Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-a agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 04; 45(8):1043-1057.
Score: 0.147
-
Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-a agents in rheumatic diseases; A systematic review and meta-analysis. J Autoimmun. 2017 May; 79:4-16.
Score: 0.146